Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis.

@article{Filippi1998GuidelinesFU,
  title={Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis.},
  author={Massimo Filippi and Mark A. Horsfield and Herman J. Ad{\`e}r and Frederik Barkhof and Paolo Bruzzi and Andrew Stephen Evans and Joseph A. Frank and Robert I. Grossman and Henry F. McFarland and Paul Molyneux and Donald W. Paty and Jack Simon and Paul S. Tofts and Jerry S. Wolinsky and David H. Miller},
  journal={Annals of neurology},
  year={1998},
  volume={43 4},
  pages={499-506}
}
The change of brain lesion load, measured on T2-weighted magnetic resonance imaging (MRI) using computer-assisted techniques, is a widely used secondary endpoint for phase III clinical trials in multiple sclerosis (MS). Collection, transfer, and analysis of the electronic data across multiple centers have all proved challenging and give rise to potential errors. However, many new acquisition schemes and postprocessing techniques have been developed; these may reduce scan times and result in… CONTINUE READING